Forward Pharma A/S (FWP): Price and Financial Metrics
GET POWR RATINGS... FREE!
FWP Stock Price Chart Interactive Chart >
FWP Price/Volume Stats
|Current price||$1.95||52-week high||$6.48|
|Prev. close||$1.81||52-week low||$1.50|
|Day high||$2.06||Avg. volume||7,484|
|50-day MA||$2.83||Dividend yield||N/A|
|200-day MA||$4.17||Market Cap||13.83M|
Forward Pharma A/S (FWP) Company Bio
Forward Pharma A/S is a Danish biopharmaceutical company developing FP187, a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications. The company was founded in 2005 and is based in Copenhagen, Denmark.
Most Popular Stories View All
FWP Latest News Stream
|Loading, please wait...|
FWP Latest Social Stream
View Full FWP Social Stream
Latest FWP News From Around the Web
Below are the latest news stories about FORWARD PHARMA A that investors may wish to consider to help them evaluate FWP as an investment opportunity.
Forward Pharma Announces Expected Delisting of its American Depositary Shares from the Nasdaq Capital Market
COPENHAGEN, Denmark, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”), today announced that that on December 16, 2022 it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that Nasdaq believes that Forward is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. We will not appeal this determination. Therefore, we expect the trading of our American Depositary Shar
Forward Pharma Announces the Decision of the Enlarged Board of Appeal of the European Patent Office in the EP2801355 Petition for Review
COPENHAGEN, Denmark, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”), today announced that the Enlarged Board of Appeal (the “EBA”) of the European Patent Office (the “EPO”) has denied Forward’s petition for review (the “Petition”) of the decision of the Technical Board of Appeal of the EPO that confirmed the revocation of the EP2801355 patent by the EPO Opposition Division in the opposition proceeding (“Opposition Proceeding”).The EBA’s rejection o
COPENHAGEN, Denmark, April 08, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2021. Our net loss for the year ended December 31, 2021 was $1.9 million, or $0.02 per share, versus a net loss of $6.4 million, or $0.07 per share, for the year ended December 31, 2020. Our research, development, general and administrative costs in
FWP Price Returns